Benzinga·Feb 25·Vandana SinghNovo Nordisk Cuts GLP-1 Drug Prices 50% Amid Clinical SetbacksNovo Nordisk cuts GLP-1 drug prices 50% to $675/month starting 2027 amid clinical setbacks and competitive pressure from rivals like Eli Lilly. LLYNVOclinical trialprice reduction
Benzinga·Feb 13·Namrata SenEli Lilly Stockpiles $1.5B in Experimental Weight-Loss Drug Ahead of FDA ReviewEli Lilly stockpiles $1.5B of experimental weight-loss drug orforglipron ahead of expected April FDA approval decision, signaling management confidence. LLYNVOFDA approvalpharmaceutical competition